Hearing Loss in Mucopolysaccharidoses: Current Knowledge and Future Directions
1
Nemours Biomedical Research, Nemours/Alfred I. duPont Hospital for Children, Wilmington, DE 19803, USA
2
Department of Communication Sciences and Disorders, West Chester University, West Chester, PA 19383, USA
3
Department of Biology, Washington University in Saint Louis, Saint Louis, MO 63130, USA
4
Department of Pediatrics, Thomas Jefferson University, Philadelphia, PA 19107, USA
5
Department of Pediatrics, Graduate School of Medicine, Gifu University, Gifu 501-1194, Japan
6
Department of Pediatrics, Shimane University, Shimane 690-8504, Japan
7
College of Health Sciences, University of Delaware, Newark, DE 19716, USA
*
Author to whom correspondence should be addressed.
Diagnostics 2020, 10(8), 554; https://doi.org/10.3390/diagnostics10080554
Received: 2 July 2020
/
Revised: 31 July 2020
/
Accepted: 2 August 2020
/
Published: 4 August 2020
(This article belongs to the Special Issue Mucopolysaccharidoses: Diagnosis, Treatment, and Management 2.0)
Mucopolysaccharidoses (MPS) are a group of lysosomal storage disorders caused by a deficiency of one of the enzymes involved in the degradation of glycosaminoglycans. Hearing loss is a common clinical presentation in MPS. This paper reviews the literature on hearing loss for each of the seven recognized subtypes of MPS. Hearing loss was found to be common in MPS I, II, III, IVA, VI, and VII, and absent from MPS IVB and MPS IX. MPS VI presents primarily with conductive hearing loss, while the other subtypes (MPS I, MPS II, MPS III, MPS IVA, and MPS VII) can present with any type of hearing loss (conductive, sensorineural, or mixed hearing loss). The sensorineural component develops as the disease progresses, but there is no consensus on the etiology of the sensorineural component. Enzyme replacement therapy (ERT) is the most common therapy utilized for MPS, but the effects of ERT on hearing function have been inconclusive. This review highlights a need for more comprehensive and multidisciplinary research on hearing function that includes behavioral testing, objective testing, and temporal bone imaging. This information would allow for better understanding of the progression and etiology of hearing loss. Owing to the prevalence of hearing loss in MPS, early diagnosis of hearing loss and annual comprehensive audiological evaluations are recommended.
View Full-Text
Keywords:
hearing loss; inner ear; middle ear; otitis media
▼
Show Figures
Figure 1
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited
MDPI and ACS Style
Wolfberg, J.; Chintalapati, K.; Tomatsu, S.; Nagao, K. Hearing Loss in Mucopolysaccharidoses: Current Knowledge and Future Directions. Diagnostics 2020, 10, 554. https://doi.org/10.3390/diagnostics10080554
AMA Style
Wolfberg J, Chintalapati K, Tomatsu S, Nagao K. Hearing Loss in Mucopolysaccharidoses: Current Knowledge and Future Directions. Diagnostics. 2020; 10(8):554. https://doi.org/10.3390/diagnostics10080554
Chicago/Turabian StyleWolfberg, Jeremy, Keerthana Chintalapati, Shunji Tomatsu, and Kyoko Nagao. 2020. "Hearing Loss in Mucopolysaccharidoses: Current Knowledge and Future Directions" Diagnostics 10, no. 8: 554. https://doi.org/10.3390/diagnostics10080554
Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.
